Do high MICs predict the outcome in invasive fusariosis?
Date
2021-03
Journal Title
Journal ISSN
Volume Title
Repository Usage Stats
views
downloads
Citation Stats
Abstract
Background
Invasive fusariosis (IF) affects mostly severely immunocompromised hosts and is associated with poor outcome. Since Fusarium species exhibit high MICs for most antifungal agents, this could explain the poor prognosis. However, a clear-cut correlation between MIC and outcome has not been established.Objective
To evaluate the correlation between MIC and outcome (6 week death rate) in patients with IF.Methods
We performed a multicentre retrospective study of patients with IF who received treatment and had MIC levels determined by EUCAST or CLSI for the drug(s) used during treatment. We compared the MIC50 and MIC distribution among survivors and patients who died within 6 weeks from the diagnosis of IF.Results
Among 88 patients with IF, 74 had haematological diseases. Primary treatment was monotherapy in 52 patients (voriconazole in 27) and combination therapy in 36 patients (liposomal amphotericin B + voriconazole in 23). The MIC50 and range for the five most frequent agents tested were: voriconazole 8 mg/L (range 0.5-64), amphotericin B 2 mg/L (range 0.25-64), posaconazole 16 mg/L (range 0.5-64), itraconazole 32 mg/L (range 4-64), and isavuconazole 32 mg/L (range 8-64). There was no difference in MIC50 and MIC distribution among survivors and patients who died. By contrast, persistent neutropenia and receipt of corticosteroids were strong predictors of 6 week mortality.Conclusions
Our study did not show any correlation between MIC and mortality at 6 weeks in patients with IF.Type
Department
Description
Provenance
Citation
Permalink
Published Version (Please cite this version)
Publication Info
Nucci, Marcio, Jeffrey Jenks, George R Thompson, Martin Hoenigl, Marielle Camargo Dos Santos, Fabio Forghieri, Juan Carlos Rico, Valentina Bonuomo, et al. (2021). Do high MICs predict the outcome in invasive fusariosis?. The Journal of antimicrobial chemotherapy, 76(4). pp. 1063–1069. 10.1093/jac/dkaa516 Retrieved from https://hdl.handle.net/10161/28608.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
Scholars@Duke
Jeffrey Daniel Jenks
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.